Table 2.

Recent prospective, randomized, controlled, double-blind Phase III studies for the causal treatment of seasonal allergic rhinitis caused by ragweed pollen

Reference	Randomized participants	Geographic region*	Multi center	Agent	Study design	Primary endpoint	Validated outcome measure?	Significant difference of primary endpoint?
Creticos et al61	784	Northern America and Eastern Europe	Yes	Sublingual allergy immunotherapy tablet (MK-3641; Merck and Co, Inc., Whitehouse Station, NJ, USA)	52 weeks, four arms: l.5 μg;6 μg; 12 μg; or placebo	Combined symptom and medication score	No	Yes(12 μg)
Nolte et al60	565	Northern America	Yes	Sublingual allergy immunotherapy tablet (MK-3641; Merck and Co, Inc.)	52 weeks, three arms: 6 μg; 12 μg; or placebo	Combined symptom and medication score	No	Yes (6 μg and 12 μg)
Skoner et al58	115	Northern America	Yes	Sublingual liquid (standardized glycerinated short ragweed pollen allergenic extract; Greer Laboratories, Inc., Lenoir, NC, USA)	17 weeks, three arms: 4.8 μg; 48 μg; or placebo	Symptom score	No	No
Bowen et al59	83	Northern America	Yes	Sublingual liquid (active product standardized ragweed allergen extract; Staloral; Stallergenes SA, Antony, France)	Ragweed season, two arms: increasing doses or placebo	Combined symptom and medication score	No	No
Mirone et al53	32	Southern Europe	Yes	Subcutaneous injection (ragweed pollen extract absorbed with aluminum hydroxide/phenolated saline solution; ALK-Abellò, Hørsholm, Denmark)	12 months, two arms: increasing doses or placebo	Not specifically designated	No	Not applicable
André et al57	110	Western Europe	Yes	Sublingual liquid or tablet (standardized ragweed extract; Stallergenes SA)	7.5 months, two arms: increasing doses or placebo	Not specifically designated	No	Not applicable

Note:

^*Geographical subregion as defined by the United Nations Organization.